EMA401

DRUG3 trials

Sponsors

Novartis Pharmaceuticals, Novartis Pharma AG

Conditions

Painful Diabetic NeuropathyPost-herpetic Neuralgianeuralgia peripheral neuropathic pain

Phase 2

Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)

TerminatedNCT03094195

Novartis PharmaceuticalsPost-herpetic Neuralgia

Start: 2017-06-27End: 2019-03-07Updated: 2021-10-08

Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)

TerminatedNCT03297294

Novartis PharmaceuticalsPainful Diabetic Neuropathy

Start: 2018-03-14End: 2019-03-25Updated: 2021-10-08

Unknown Phase

A single-center, open-label, single oral dose study to investigate the absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetics of EMA401 after a single dose of [14C]EMA401 in healthy male subjects

Active, not recruitingNL-OMON44485

Novartis Pharma AGneuralgia peripheral neuropathic pain

Start: 2017-07-27Target: 6Updated: 2024-02-28